Toggle menu

REACT Study

Start date:
Nov 2019
End date:
Dec 2019
Co-ordinated by:
Lumira Dx
Main trial site:
RIE, Edinburgh

A performance evaluation study designed to assess the precision and accuracy of the Lumira DX point of care (POC) and C-Reactive (CRP) assay as an aid in the detection and evaluation of infection, tissue injury and inflammatory disorders.

 

In the emergency department (ED), CRP is tested in patients presenting with a variety of symptoms as an aid the detection and evaluation of infection, tissue injury or inflammatory disorders.

 

 

Primary objective  – To determine the performance of the LumiraDx POC CRP assay when compared to the Siemens Dimension reference method in patients with symptoms of infection, tissue injury and inflammatory disorders.

 

Sample size –  50 participants over a duration of approximately 4 weeks.

 

Chief Investigator

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

Research Team

Julia Grahamslaw

Lead Research Nurse

Nicky Freeman

Senior Research Nurse

More EMERGE Trials

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Prospective multicentre observational study conducted over one calendar month in 2019, with the aim of describing the epidemiology of non-trauma related headache in adults presenting to emergency departments including investigations, treatments and outcome.

This will include adult patients presenting to the ED with non-trauma-related headache as their primary complaint.

Read more

HEAD Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)

Read more

SABER Study

Developing a molecular tool to stratify the acute joint presentation: facilitating early diagnosis of septic arthritis (Septic Arthritis Biomarker Emergency Rule-out - SABER)